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Abstract
p53 gene alterations are among the most common events
observed in colorectal cancer, and are accompanied
frequently by DNA aneuploidy and high proliferative
activity. The prognostic significance of such mutations
remains controversial. We prospectively evaluated the
prognostic significance of p53 mutations, DNA-ploidy,
and S phase fraction (SPF) in a consecutive series of 160
colorectal cancer patients (median follow-up 71 months).
Tumor DNA was screened for p53 mutations by PCR/
single-strand conformational polymorphism/sequencing.
DNA-ploidy and SPF were assessed by DNA flow
cytometry. p53 mutations were detected in 68 of 160
(42.5%) cases. In 56% (38 of 68) of these, p53 mutations
were found in conserved areas of the gene and in 44%
(30 of 68 cases) outside the conserved regions. Eighteen of
the 68 cases (26%) had mutations in the L3 loop, 11 of 68
(16%) in the L1 loop-sheet- helix motif, and 39 of 68
(58%) outside L3 and loop-sheet- helix. Seventy-five
percent of the cases (120 of 160) showed DNA
aneuploidy, whereas 18% of these (22 of 120) were
multiclonal. The major independent predictors for both
disease relapse and death were advanced Dukes’ stage,
p53 mutations affecting L3 loop, DNA-aneuploid tumors,
and high SPF (>18.5%). Our results show that mutations
in L3 functional domain, more than any mutations, are
important biological indicators to predict the outcome of
patients indicating that these mutations have biological
relevance in terms of colorectal cancer disease course.
Introduction
The classic adenoma-carcinoma sequence in CRC4 results from
an accumulation of somatic genetic changes responsible for a
progressively more aggressive cell behavior (1). These alter-
ations, which may range from single nucleotide substitutions,
deletions and insertions, to rearrangements, amplifications, and
loss of genetic material often resulting in gross variations in cell
DNA content (DNA-ploidy), are ultimately responsible for the
activation of proto-oncogenes and the inactivation of tumor
suppressor genes leading to uncontrolled proliferative activity.
It has been suggested that characterization of the genomic
abnormalities acquired during colorectal tumorigenesis might
provide additional prognostic information. However, although
multiclonality would seem to be a frequent indicator of worse
clinical outcome (2, 3), the available data regarding the prog-
nostic significance of DNA-ploidy in CRCs are still controver-
sial (4), whereas the prognostic value of SPF as a measure of
the proliferative activity of the cancer cells is more clearly
established (5). Mutations of the p53 gene have been observed
in 50% of CRCs, as well as in other neoplastic diseases,
mostly in the protein core domain (6). The integrity of this
region, which includes 4 of the 5 domains highly conserved
among species (area II, codons 112–141; area III, 171–181;
area IV, 234–258; and area V, 271–286), appears essential for
the DNA-binding and transcriptional regulatory activity of p53
(7), which in response to DNA damage or other forms of
cellular stress activates and coordinates multiple pathways
leading to cell cycle arrest, in G1-S, G2-M, or to apoptosis (8).
Within this region, several structural domains with distinct
roles have been identified: the L2 loop (codons 163–195),
required for the folding and stabilization of the central part of
the protein; the L3 loop (codons 236–251), and the LSH motif
(codons 273–286) within which at least two residues (241, 248
and 273, 280, respectively) contact the DNA directly (Ref. 9;
Fig. 1). Most studies performed to evaluate the prognostic
significance of p53 mutations in CRCs have taken into account
any mutation of the gene, usually on analysis of the region
spanning exons 5–8 (codons 130–286), and the results obtained
thus far have proved to be rather discordant (6), with only some
of them indicating an influence of p53 mutations on DFS and
OS rate (10, 11). However, as suggested by Borresen-Dale et al.
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(12), p53 mutations affecting regions that are important for
particular functions of the protein may have a stronger prog-
nostic impact. Moreover, p53 mutations in evolutionary con-
served regions were found to be associated with tumors that are
not only biologically more aggressive (13), but probably also
chemoresistant (14). Support to these findings is provided by
the more recent report by Skaug et al. (15) that mutations within
specific domains (L2 loop, L3 loop, and LSH motif) of p53 are
associated with a more aggressive phenotype, presumably be-
cause these mutations have a particularly strong negative effect
on the biological activity of the protein.
Therefore, the aim of our prospective study was to assess
in 160 patients who had undergone curative surgical resection
for primary CRC the possible association between any or spe-
cific p53 mutations, DNA-ploidy, SPF, and the clinicopatho-
logical variables, and, furthermore, to evaluate the prognostic
significance of the biomolecular variables themselves.
Materials and Methods
Patient Features. A prospective study was performed on
paired tumor and normal colon tissue samples from a consec-
utive series of 160 patients undergoing resective surgery for
primary operable CRC at a single institution (Department of
Oncology, University of Palermo, Palermo, Italy) from January
1988 to December 1992.
Elegibility criteria used were: (a) electively resected pri-
mary CRC; (b) processing of fresh paired normal mucosa-
tumor samples within 30 min after tumor removal; (c) available
DNA from normal and tumor tissue for biomolecular analyses;
and (d) access to accurate follow-up information. Briefly, the
following exclusion criteria were used: (a) history of previous
neoplasias; (b) patients from families with familial adenoma-
tous polyposis or hereditary nonpolyposis CRC with a highly
penetrant genetic predisposition to CRC; (c) synchronous or
metachronous CRC; and (d) chemotherapy or radiation therapy
before surgery. A resection of the primary CRC was performed
in all of the cases. A total of 137 patients was potentially cured
by radical surgical tumor resection with regional en bloc
lymphadenectomy proximally up to the origin of the vascular
trunks. Twenty-three patients had either nonradical surgery or
distant metastases. To avoid evaluator variability in the pa-
tients, all of the resection specimens and microscopic slides
were meticulously examined by two independent pathologists
(R. M. T. and M. M.), who were not aware of the original
diagnosis and of the results of the molecular analyses. The
complete excision of the primary tumor was proven by the
histopathological examination on 3–5 consecutive 4 m-thick
sections of the proximal and distal resected margins, respec-
tively. All of the tumors were histologically confirmed to be
CRCs. In addition, the pathologists assessed tumor site (prox-
imal or distal tumors), tumor size, pathological stage, tumor
grade (histological differentiation), presence or absence of
lymph node metastases, tumor growth (expansive or infiltra-
tive), tumor type (adenocarcinoma NOS or mucinous), pres-
ence or absence of vascular and lymphatic invasion or tumor
lymphocytic infiltrate. According to Turnbull’s modification of
Dukes’ system (16) the tumors were staged from A to D.
Mucinous carcinomas were defined by the presence of mucin in
50% of the tumoral area as determined from the available
histological sections. Finally, metastatic cases were identified
by clinical and histopathological analyses of neoplastic cells in
organs such as the lymph nodes, the liver, and so on, along with
the primary tumor. Patients with Dukes’ stage A and B CRC
were treated with surgery alone, whereas only 10 patients with
Dukes’ stage C received adjuvant chemotherapy with 5-flu-
orouracil, leucovorin, and levamisole, because in the pre-1991
period almost none of the patients received adjuvant treatment.
Patients with nonradical surgery and/or distant metastases were
treated by 5-fluorouracil and leucovorin. Postoperatively, all of
the patients were checked at 3-monthly intervals for the first 2
years, at 6-monthly intervals for the next 2 years, and annually
thereafter. The follow-up program included a clinical exami-
nation, blood tests (including carcinoembryonic antigen assay),
annual chest radiography, and endoscopy. Abdominopelvic
computed tomography scan was also performed each year for
the first 2 years. Disease relapse (local recurrence or distant
Fig. 1. Schematic representation of the p53 protein structural domains (a), highly conserved regions of p53 gene (b), and mutation hot spots in CRC as reported in
literature (c).
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metastases) was confirmed histologically where possible. Writ-
ten informed consent was obtained from all of the patients
included in this study. Information on survival (DFS and OS)
was obtained directly from clinical charts and through the
Oncology Section at our Institution. Clinicopathological and
follow-up data of all of the patients have been recorded pro-
spectively in a computerized registry database (Table 1).
Tissue Handling and DNA Extraction. Multiple samples (6–
10) of the primary tumor tissue were taken from different tumor
areas (including the core and the invasive edge of the tumor).
The portion of primary tumor was obtained by superficial
biopsy of either the tumor bulk or the edge of the malignant
ulcer for more infiltrative cancer. All of the tissues were care-
fully trimmed to remove as much non-neoplastic tissue as
possible, avoiding the nonviable areas. Furthermore, multiple
samples of normal mucosa (as confirmed by histology) were
taken from a macroscopically uninvolved area 20–40 cm away
from the tumor site, to be used as control for biomolecular and
flow-cytometric analysis. The tissues were bisected, one-half of
each sample was processed for pathological examination, and
the remaining half of the sample pool was immediately frozen
and stored at 80°C until analyzed. The adequacy of the
material was checked on frozen tissue sections, and only tissue
samples with 80% tumor content were used in subsequent
biomolecular and flow-cytometric analysis. Where present, ar-
eas with a high content of non-neoplastic cells were removed
from the frozen block with a scalpel. Evaluation of each bi-
omolecular variable (p53 alterations, DNA-ploidy, and SPF)
was performed independently by researchers who had no
knowledge of the clinical data for the samples. High molecular
weight genomic DNA was extracted as described previously
(17) from primary CRC and normal colon specimens.
Detection of p53 Gene Mutations. Mutations within the p53
gene were detected by SSCP analysis following PCR amplifi-
cation of the exons 5–8, performed as described previously
(18). In every instance, negative (DNA was replaced with
water) controls were amplified by PCR and included in the
experiment. In all of the PCR assays aerosol-resistant pipette
tips were used to avoid cross-contamination. The quality and
the concentration of the amplification products were verified by
1.5% agarose gel electrophoresis and ethidium bromide stain-
ing. One-hundred ng aliquots of the amplified DNA fragments,
purified and concentrated by filtration through Microcon 50
columns (Amicon, Beverly, MA) were denatured and analyzed
by SSCP analysis. PCR-SSCP analysis was repeated twice for
each sample to minimize the possibility of artifacts because of
contamination or polymerase errors, and interpretation of SSCP
analysis was performed by consensus of two investigators.
DNA of normal colon tissue from each patient was also am-
plified and run in parallel with matched tumoral DNA samples
on SSCP gels, to evaluate the occurrence of germ-line muta-
tions or polymorphisms. Individual single-strand DNA frag-
ments with shifted mobilities, compared with normal control,
were electroeluted from polyacrylamide gel, reamplified, and
sequenced as described previously (19).
Flow-Cytometric Analysis. DNA flow cytometric examina-
tion was performed on samples of frozen healthy mucosa and
tumor tissue as described previously (20, 21). Briefly, after
being thawed a room temperature, the samples were mechani-
cally disaggregated. The suspension was subsequently diluted
to a concentration of 2  106 nuclei/ml. One aliquot of the
suspension was used for the preparation of standard reference
slides stained with Papanicolaou stain to confirm the presence
of tumoral nuclei. For the DNA analysis, the nuclei were
stained in a solution containing 50 g/ml propidium iodide
(Calbiochem, La Jolla, CA), 50 mg/ml RNase A (Sigma Chem-
ical Co., St. Louis, MO), and 0.03% NP40 (Sigma) for 30 min
at room temperature in the dark. Before staining, a cellular
suspension obtained from healthy mucosa was added to each
sample as a internal standard reference. A FACSort flow cy-
tometer (Becton Dickinson, CA) was used to obtain data. The
suspension of tumoral nuclei (ranging from 20,000 to 65,000)
and those used as standard reference were measured both sep-
arately and after mixing. Double or triple DNA measurements
were performed on all of the samples.
DNA ploidy status was expressed as a DI (22). Tumors
with a DI of 1 were defined as DNA diploid, and tumors with
lower or higher DI values were considered DNA aneuploid if
they contained 10% aneuploid cells. The DNA-aneuploid
results were additionally subdivided into monoclonal (with
only one DNA-aneuploid peak) and multiclonal (with two or
more DNA-aneuploid peaks). Proliferative activity was ex-
pressed as the fraction of cells in the S phase of the cell cycle.
SPF was calculated according to a program using the mathe-
matical method of Dean and Jett with Multicycle software
Table 1 Patient characteristics (n  160)
No. patients
Sex
Male 76
Female 84
Age
55 29
55–75 96
75 35
Site
Proximal tumor 31
Distal tumor 129
Tumor size (cm)
5 60
5 100
Dukes’ stage
A 40
B 51
C 41
D 28
Node status
Negative 101
Positive 59
Tumor growth
Expansive 20
Infiltrative 140
Tumor grade
Well differentiated (G1) 23
Moderately differentiated (G2) 104
Poorly differentiated (G3) 33
Tumor type
Adenocarcinoma NOS 137
Mucinous 23
Lymphoemative invasion
None 45
Present 115
Lymphocitic infiltrate
Prominent 48
Nonprominent 112
Surgery
Curative resection 137
Noncurative resection 23
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(Phoenix Flow Systems, San Diego, CA), including systematic
background subtraction (23).
Statistical Analysis. Fisher’s exact test (StatXact Turbo; Cytel
Software Corporation, Cambridge, MA) was used to evaluate
the associations between biological variables. The relationship
of different prognostic variables to DFS and OS was assessed
univariately by the Kaplan and Meier method. Survival time
was calculated from the date of surgery to the date of death
(cancer-related causes) or last follow-up, with times censored
for patients dying of causes unrelated to CRC and those sur-
viving. DFS was measured from the day of primary surgery to
the date of the first relapse (locoregional or metastatic). Sig-
nificant differences among survival curves were checked by the
log-rank test and Wilcoxon test, or a test for trend when
appropriate. Multivariate analysis was carried out by Cox pro-
portional hazards model, using a backward procedure (24).
Ps  0.05 were considered significant.
Results
Mutation Analysis of p53 Gene. Mutation analysis of exons
5–8 of the p53 gene was performed on genomic DNA from
primary CRCs of 160 patients by the PCR-SSCP technique.
The absence of abnormal bands was assessed in at least two
independent PCR-SSCP analyses for each exon. Aberrantly
migrating bands were found in 42.5% (68 of 160) of the cases
(Fig. 2). Sequence analysis of the DNA fragments with altered
electrophoretic mobility made it possible to establish the exact
site and nature of the genetic alteration in 65 tumor samples.
Overall, 84 p53 mutations were identified in 68 of the 160
screened CRCs, and sequence data were obtained for 81. The
features of the p53 mutations are summarized in Table 2. Of the
84 mutations, 19% (16 of 84) were in exon 5, 32% (27 of 84)
in exon 6, 36% (30 of 84) in exon 7, and 13% (11 of 84) in exon
8. Fourteen tumor samples were found to harbor two (9 in the
same exon and 3 in two different exons) or three (2 in two
different exons) different p53 mutations. Nineteen of the 81
sequenced mutations (23%) were found to be frameshifts (15
microdeletions and 4 microinsertions), whereas 62 (77%) were
single-nucleotide substitutions. Eighty-two percent (51 of 62)
of the latter were missense (45 of 62) or nonsense (6 of 62)
mutations, whereas silent mutations were found in 11 cases (9
of them being in codon 213, a site of polymorphism identified
previously). Moreover, transitions (81%, 50 of 62) were far
more frequent than transversions (19%), G:C to A:T mutations
(50% at CpG sites) being the most frequently represented
(76%). Forty-two different mutations spanned 32 codons,
whereas 30 mutations (37%) clustered in 4 codons: 9 cases each
in codons 248 and 249, 7 cases in codon 244, and 5 cases in
codon 273. No germ-line mutations were found indicating that
in every case the change was somatic. Fifty-seven percent of the
mutations (48 of 84) occurred in highly conserved domains
(areas II-V). Accordingly, tumors with p53 mutations were
classified in two groups: 56% of the cases (38 of 68 cases) with
mutations in conserved areas of the p53 gene (conserved) and
44% (30 of 68 cases) with mutations outside the conserved
areas (nonconserved). In addition, by taking into account the
specific functional and structural domains of p53 affected by
the mutations, the cases were also classified as follows: 18 of
68 cases (26%) with mutations of the L3 loop, 11 of 68 cases
(16%) with mutations of the LSH motif, and 39 of 68 cases
(58%) with mutations outside L3 loop and LSH. Because silent
mutations do not determine any amino acid change in the
protein, they have been included in the wild-type group for
statistical analysis.
Cellular DNA Content Evaluation. Adequate DNA histo-
grams were obtained for all of the normal and tumoral tissues
by flow cytometry. The coefficients of variation of the DNA-
diploid peak ranged from 2.5 to 4.8% (median 3.4%). DNA
aneuploidy was found in 75% of the cases (120 of 160),
whereas 18% of these (22 of 120) showed multiclonality. Fig.
3 shows the distribution of the DI values in the 120 DNA-
aneuploid cases.
SPF Evaluation. The SPF ranged from 2.1 to 32.6% (median:
18.3% and interquartile range: 14.1–21.7%). By using the SPF
median value as a cutoff point, tumors were accordingly di-
vided into low (18.3%) and high (18.3%) SPF tumors.
Relationship between Biomolecular Indicators and Clinical
Data. p53 mutations in the conserved regions were more fre-
quent in distal cancers (P  0.05), in DNA aneuploid (P 
0.01), and in high SPF tumors (P  0.01; Table 3). Moreover,
p53 mutations affecting L3 loop were significantly associated
with high SPF (P  0.05; Table 4). No significant relationship
was seen between the presence (any mutations) or type of p53
mutations (missense versus frameshift and transitions versus
transversions versus frameshift) and the clinicopathological
variables analyzed. DNA aneuploidy was associated with distal
tumors (P 0.01), histological grade (G3; P 0.05), advanced
Dukes’ stage (C and D; P 0.01), lymph node metastases (P
0.01), and high SPF. The median SPF of DNA-aneuploid tu-
mors was 19.2%, whereas that of the DNA-diploid tumors was
12.4% (P  0.01; Table 4).
Uni- and Multivariate Analysis of Prognostic Factors. The
median follow-up time in our study group was 71 months
(range 34–115 months). The median survival of the whole
group was 43 months. At univariate analysis, distal cancers,
advanced Dukes’ stage, node status positive, lymphohematic
invasion, DNA aneuploidy, and high SPF, the presence, type
(frameshift), or site (in conserved regions, affecting L3) of p53
mutations proved to be significantly related to quicker relapse,
whereas these same factors, and in addition infiltrative tumor
growth, prominent lymphocytic infiltration, and noncurative
resection, were significantly related to shorter OS (Table 5).
Fig. 4 shows the probability of DFS (Fig. 4a) and OS (Fig. 4b)
according to p53 mutations in specific structural domains. The
significant variables at univariate analysis were entered in a
Cox proportional hazards model with backward elimination.
The major significant predictors for both disease relapse and
death were advanced Dukes’ stage, aneuploid tumors, high
SPF, and p53 mutations affecting L3 loop, whereas lymphohe-
matic invasion was the only independent factor for relapse and
noncurative resection for death (Table 6).
Fig. 2. SSCP analyses of exon 6 of the p53 gene, amplified from CRC and
mucosa genomic DNA of 3 patients. In each pair of lanes the normal tissue DNA
is at the left and the tumor DNA is at the right. The extra bands visualized in lines
2, 4, and 6 correspond to single-strand DNA molecules harboring mutations in
codon 195 (ATC to TTC), 192 (CAG to TAG), and 206/207 (TTG to TT- and
GAT to -AT, respectively) as confirmed by sequencing. Lane 7 shows negative
control (Ct) DNA wild-type.
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Table 2 Localization and type of mutations in 68 patients with CRC
Sample Mutated exon Mutated codon Nucleotide change Amino acid change Type mutation CD Zn-BD
3 K 7 248 cgg3tgg arg3trp Missense Y L3
6 K 6 195 atc3ttc ile3phe Missense N L2
13 K 8 273 cgt3cat arg3his Missense Y LSH
19 K 5 158 cgc3cac arg3his Missense N
26 K 7 238 tgt3tat cys3tyr Missense Y L3
249 agg3ag- arg3 Frameshift Y
27 K 5 155 acc3ac- thr3 Frameshift N
28 K 5 174 agg3aag arg3lys Missense Y L2
30 K 5 141 tgc3tac cys3tyr Missense Y
35 K 5 151 ccc3tcc pro3ser Missense N
36 K 5 158 cgc3cac arg3his Missense N
63 K 6 204 gag3tag glu3STOP Nonsense N
206 ttg3tag leu3STOP Nonsense N
70 K 7 244 ggc3agc gly3ser Missense Y L3
249 agg3ag- arg3 Frameshift Y
77 K 8 272 gtg3atg val3met Missense Y LSH
102 K 7 248 cgg3tgg arg3trp Missense Y L3
110 K 7 244 ggc3agc gly3ser Missense Y L3
249 agg3ag- arg3 Frameshift Y
114 K 5 141 tgc3cgc cys3arg Missense Y
6 204 gag3tag glu3STOP Nonsense N
125 K 7 248 cgg3tgg arg3trp Missense Y L3
130 K 7 248 cgg3tgg arg3trp Missense Y L3
147 K 8 282 cgg3tgg arg3trp Missense Y LSH
172 K 5 158 not sequenced N
191 K 6 192 cag3tag gln3STOP Nonsense N L2
195 K 7 244 ggc3agc gly3ser Missense Y L3
249 agg3ag- arg3 Frameshift Y
207 K 6 213 cga3cgg arg3arg Silent N
221 K 7 248 cgg3tgg arg3trp Missense Y L3
234 K 5 152 ccg3cct pro3pro Silent N
237 K 6 196 cga3ctga arg3 Frameshift N
245 K 6 220 tat3tgt tyr3cys Missense N
254 K 7 248 cgg3tgg arg3trp Missense Y L3
333 K 7 255/ atc/aca3 ile/thr3 Frameshift Y
/256 at-/–a ile/-
334 K 7 253 acc3ac- thr3 Frameshift Y
255 atc3a-c ile3 Frameshift Y
338 K 7 244 ggc3agc gly3ser Missense Y L3
249 agg3ag- arg3 Frameshift Y
344 K 6 201 ttg3ttc leu3phe Missense N
351 K 5 152 ccg3cccc pro3 Frameshift N
368 K 6 202 cgt3cgct arg3 Frameshift N
371 K 7 248 cgg3tgg arg3trp Missense Y L3
398 K 6 220 tat3tgt tyr3cys Missense N L3
7 244 ggc3agc gly3ser Missense Y
249 agg3ag- arg3 Frameshift Y
406 K 5 174 agg3aag arg3lys Missense Y L2
416 K 6 213 cga3cgg arg3arg Silent N L3
7 248 cgg3cag arg3gln Missense Y
249 agg3ag- arg3 Frameshift Y
421 K 5 177 ccc3cc- pro3 Frameshift Y L2
424 K 6 213 cga3tga arg3STOP Nonsense N
427 K 5 141 tgc3tac cys3tyr Missense Y
449 K 6 213 cga3cgg arg3arg Silent N
452 K 7 248 cgg3tgg arg3trp Missense Y L3
463 K 8 273 cgt3cat arg3his Missense Y LSH
466 K 6 214 cat3caat his3 Frameshift N
468 K 6 213 cga3cgg arg3arg Silent N
8 282 cgg3tgg arg3trp Missense Y LSH
499 K 8 278 cct3tct pro3ser Missense Y LSH
508 K 6 193 cat3cag his3gln Missense N L3
7 242 tgc3tac cys3tyr Missense Y
543 K 8 272 gtg3atg val3met Missense Y LSH
552 K 8 273 cgt3cat arg3his Missense Y LSH
558 K 6 213 cga3tga arg3STOP Nonsense N
569 K 6 213 cga3cgg arg3arg Silent N
620 K 6 213 cga3cgg arg3arg Silent N
627 K 5 151 ccc3acc pro3thr Missense N
629 K 6 not sequenced N
638 K 6 213 cga3cgg arg3arg Silent N
645 K 8 273 cgt3cat arg3his Missense Y LSH
677 K 6 206/ ttg/3tt-/leu/3 Frameshift N
/207 /gat/-at/asp
678 K 7 244 ggc3gcc gly3ala Missense Y L3
249 agg3cgg arg3arg Silent Y
686 K 6 206/ ttg/3tt-/ leu/3 Frameshift N
/207 /gat/-at/asp
700 K 6 213 cga3cgg arg3arg Silent N
713 K 8 278 cct3tct pro3ser Missense Y LSH
706 K 5 163 tac3ttc tyr3phe Missense N L2
747 K 6 213 cga3cgg arg3arg Silent N
757 K 5 141 tgc3tcc cys3ser Missense Y
789 K 8 273 cgt3cat arg3his Missense Y LSH
817 K 7 244 ggc3agc gly3ser Missense Y L3
249 agg3ag- arg3 Frameshift Y
861 K 6 not sequenced N
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Discussion
Previous analyses performed by several researchers on different
types of tumors has shown that most of the p53 mutations
(95%) affect exons 5–8, which code for residues 130–286,
the most important region for the folding and, therefore, for the
stabilization of the tertiary structure of the protein (core do-
main), and which contains the site-specific, DNA-binding do-
main (9).
In our screen for mutations in exons 5–8 of p53 on
genomic DNA from primary CRCs of 160 patients, we ob-
served a mutation frequency of 42% (68 of 160), within the
fairly wide range of values reported previously in CRC (23–
61%) (10, 11, 25–28). This variability can be explained by
several factors, such as the different methods used to assess p53
mutations (SSCP, denaturing gradient gel electrophoresis, tem-
perature gradient gel electrophoresis, and direct sequencing),
the type of tumor storage (fresh/frozen tissue and paraffin-
embedded blocks), an intrinsic tumoral heterogeneity, and, in
addition, more specific features of the patient cohorts entered in
the study, in particular, histopathologic staging and grading of
the tumor. In fact, patients at an advanced Dukes’ stage (C and
D) and/or with poorly differentiated tumors (G3) generally
present a higher rate of p53 mutations (28, 29). In accordance
with several other reports (10, 26, 28), 57% of all of the
mutations observed in our series (48 of 84) were in four of the
five highly conserved areas of the gene, which include two
important regions for p53 binding to DNA. One of these con-
tains the amino acids needed for DNA interaction, in particular
those that are part of the L3 Zn-BD and of the LSH motif. In
our own series, 21% (18 of 84) of the mutations occurred in L3
and 13% (11 of 84) in LSH, in accordance with the results
reported by Borresen-Dale et al. (12). Our data confirm that
arginines 248 and 273, amino acids of these domains interact-
ing directly with DNA, are among the most frequently mutated
residues (in our series: 9% and 5%, respectively). On the
contrary the absence of codon 175 mutations in our series
suggests that mutations at specific codons may be an indication
of specific exposures to toxic agents or of genomic suscepti-
bility. The second region, which, when mutated, is also respon-
sible for the loss of p53 DNA-binding capacity includes the
amino acids localized in L2, and needed for the folding and
stabilization of the central domain (9). Mutations in this area
were observed less frequently in our own series (7%).
Flow-cytometric analysis of CRCs shows DNA aneu-
ploidy rates ranging from 39 to 89% (4, 30). The aneuploidy
rate (75%) observed in our study is among the highest thus far
reported in the literature, probably for two main reasons: (a) the
multiple sampling performed in all of the cases studied, which
Fig. 3. Distribution of the DI values in 120 DNA-
aneuploid cases (98 monoclonal and 22 multiclonal).
Table 3 Relationships of p53 mutations in the highly conserved domains or in the functional/structural domains, and clinicopathological and biological variables of
the 160 CRC patients
p53
No mutation
(%)
Nonconserved
(%)
Conserved
(%) P L3 (%) LSH (%)
Outside L3/
LSH (%) P
Total 100 (62) 22 (14) 38 (24)
Site
Proximal tumors 26 (84) 3 (10) 2 (6)
Distal tumors 74 (57) 19 (15) 36 (28) 0.05
DNA ploidy
Diploid 35 (88) 2 (5) 3 (7)
Aneuploid 65 (54) 20 (17) 35 (29) 0.01
SPF
18.3 60 (74) 10 (12) 11 (14) 4 (5) 5 (6) 12 (15)
18.3 40 (51) 12 (15) 27 (34) 0.01 14 (18) 6 (8) 17 (22) 0.05
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considerably reduces the probably of missing aneuploid clones
at analysis; in fact, CRCs are heterogeneous, both from the
histopathologic point of view and also with regard to cellular
DNA content (31, 32); and (b) the choice of freezing to 80°C
rather than paraffin-embedding as sample storage method. Al-
though the analysis of paraffin-embedded samples permits the
retrospective evaluation of many cases with suitable follow-up,
this type of storage may compromise the reliability of the
results, because of the presence of a relatively large quantity of
debris, to poor histogram resolution and to high coefficients of
variation.
Our results show a significant relationship between p53
mutations in the conserved regions and flow-cytometry param-
eters, and also an association between DNA aneuploidy and
SPF. The association between p53 mutations in the conserved
regions, and aneuploidy and high SPF may be related to the
well-known role played by p53 as a brake to the cell cycle and
as guardian of the integrity of the genome. Interestingly, we
additionally found that p53 mutations in the L3 domain are
associated only with high SPF and not with aneuploidy. This
might be taken as an indication that the pathways through
which p53 restrains cell proliferation and prevents mitosis in
cells with aberrant mitotic spindles are activated independently
by p53, and that its function as a transcriptional regulator is
differentially affected by mutations in L3 loop versus mutations
in other adjacent conserved regions. In the first case, only a
subset of the genes regulated by p53 would no longer be under
its control, whereas in the second, p53 would also lose its
capacity to interact with additional promoters, and thus acti-
vate/repress the transcription of a larger number of (or even all)
its target genes. Should this interpretation of our data be con-
firmed by additional studies, this may be the first evidence of
a direct correlation between specific p53 mutations and loss of
distinct functional properties of p53 in vivo. The association
between DNA-aneuploidy and high SPF found in our study
might result from higher proliferative activity of the aneuploid
clones or else from a prolongation of S phase in an altered cell
cycle with a higher risk of additional genetic alterations and
higher probability of development of populations containing
aneuploid DNA. In accordance with Jernvall et al. (33), we
observed a higher incidence of mutations in the conserved areas
of p53 in distal CRC, as well as a significant association
between DNA ploidy and the primary tumor site: as in most of
the reports in literature (34–36), we too found a higher rate of
aneuploidy in distal CRC and higher diploidy in proximal
CRCs. These data, together with the observation that microsat-
ellite instability is found mainly in diploid tumors and in those
of the proximal colon (37), support the hypothesis of Beart et
al. (38), that carcinomas of the proximal and distal large intes-
tine may well be “biologically different diseases” reflecting
distinct carcinogenic pathways.
In our prospective study, based on univariate and multi-
variate analyses with established prognostic indicators (such as
Dukes’ stage, tumor grade, and lymphohematic invasion), we
have found that DNA ploidy, SPF, and p53 mutations affecting
the L3 region, but not any mutation or other specific subgroups
of mutations in p53, are significant and independent prognostic
factors for DFS and OS in patients with CRC who have un-
dergone surgical resection. This finding confirms and extends
recent reports on the prognostic significance of p53 mutations,
which is still a matter of debate in the literature. In fact, whereas
in several studies in which any p53 mutations identified in the
tumoral cells were taken into account, they were found to be a
significant prognostic factor (10, 11, 27), in others they did not
appear to have any relation with clinical behavior (26, 29, 39).
However, those studies in which mutations in specific domains
of p53, rather than any mutation, were considered, provide
promising results, indicating that not all of the mutations affect
p53 biological properties in the same way and suggesting that
specific mutations in regions that are important for protein
function have a more significant prognostic impact than any
p53 mutations (28). Nevertheless, even studies involving mu-
tations in highly conserved p53 areas have not provided defin-
itive evidence on this point. In fact the prospective study
Table 4 Relationships of DNA ploidy to clinicopathological and biological
variables of CRCs
DNA ploidy
PDiploid Aneuploid
n % n %
Total 40 25 120 75
Site
Proximal tumors 19 61 12 39
Distal tumors 21 16 108 84 0.01
Tumor grade
G1 12 48 13 52
G2 21 21 81 79 0.05
G3 7 21 26 79
Dukes’ stage
A  B 30 33 61 67
C  D 10 14 59 86 0.01
Node status
Negative 32 32 67 68
Positive 8 13 53 87 0.01
SPF
18.3% 32 40 47 60
18.3% 8 10 73 90 0.01
Table 5 Kaplan-Meier DFS (n  138) and OS (n  160) analysis of
biological variables in patients with CRC
No.
patients
DFS (%)
5 yrs P
No.
patients
OS (%)
5 yrs P
DNA-ploidy statusa
Diploid 38 75 40 77
An. Monoclonal 81 34 98 33
An. Multiclonal 19 10 0.01 22 9 0.01
SPFb
18.3% 72 60 81 59
18.3% 66 22 0.01 79 21 0.01
p53c
No mutations 88 51 100 49
Any mutations 48 25 0.01 58 26 0.01
No mutations 88 51 100 49
Mutation in nonconserved
areas
19 32 20 40
Mutation in conserved
areas
29 21 0.05 38 18 0.05
No mutations 88 51 100 49
Mutation outside L3/LSH 26 27 29 34
Mutations in LSH 9 33 11 27
Mutations in L3 13 15 0.05 18 11 0.01
No mutations 88 51 100 49
Missense mutations 33 24 39 28
Frameshift mutations 14 29 0.05 18 22 0.05
a All DNA-aneuploid subgroups are compared with patients with DNA-diploid
tumors.
b All high SPF subgroups are compared with patients with low SPF tumors.
c All mutation subgroups are compared with patients with no mutations (wild-
type p53).
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conducted by Goh et al. (28) on 192 CRCs has shown that
tumors with such mutations were more aggressive than those
with mutations in other areas; on the contrary, Kressner et al.
(10) found in 189 CRCs that mutations occurring outside con-
served regions were associated with a more unfavorable prog-
nosis. A clearer picture results from studies regarding mutations
within the L2, L3, and LSH domains; analyses of tumors in
different regions of the body (head and neck, esophagus, breast,
Fig. 4. DFS (a) and OS (b) of 160 patients with CRC
according to p53 functional and structural domains.
Table 6 Cox proportional hazards analysis to predict the HR of relapse or death in CRC patients
Relapse (n  138) Death (n  160)
HR
(95% confidence interval) P
HR
(95% confidence interval) P
Dukes’ stage
D vs. A 3.20 (1.32–7.71) 0.01 7.29 (3.08–17.2) 0.01
Surgery
Noncurative resection vs. curative resection 3.85 (1.74–8.49) 0.01
DNA ploidy
An. Monoclonal vs. Diploid 2.63 (1.25–5.49) 0.01 2.26 (1.12–4.59) 0.05
An. Multiclonal vs. Diploid 6.40 (2.75–14.9) 0.01 5.04 (2.25–11.3) 0.01
p53
L3 vs. no mutation 2.14 (1.06–4.32) 0.05 2.29 (1.24–4.25) 0.01
SPF
18.3% vs. 18.3% 2.64 (1.62–4.31) 0.01 2.23 (1.40–3.54) 0.01
Lymphohematic invasion
Present vs. none 2.26 (1.25–4.11) 0.01
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lung, and ovary) have demonstrated that mutations in these
areas have a strong clinical impact (15, 40–44). More specif-
ically, in the only study published thus far on CRCs (12), based
on univariate analysis of 222 cases, mutations involving L3
were associated with shorter survival rate. As Skaug et al. (15)
has suggested, because L2, L3, and LSH domains mutations
destabilize the DNA protein-binding domains more than any
other type of mutation, they might alter more drastically the
biological function of p53 and might thus contribute to the
development of clinically more aggressive tumors; they are
probably also more resistant to chemotherapy (14). The data
resulting from the present study would confirm the tendency of
these reports. We found, in fact, that p53 mutations in the L3
domain were significantly associated with risk of disease re-
lapse and of death in CRCs, and can be considered as inde-
pendent prognostic variables. Whether cell DNA content is a
significant prognostic factor in CRC is still not clear from the
data reported in literature (4). Whereas several research groups
have suggested that DNA ploidy is an independent variable (36,
45, 46), others have reported that this biological variable is not
associated with clinical outcome in CRC (47–49). These con-
flicting results may be partly because of several factors, such as
patient selection, number of cases studied, intratumoral heter-
ogeneity, sampling methods, analytic techniques, lack of stand-
ardization and inadequate control of the techniques from one
laboratory to another, and interpretation of results. From the
clinical point of view, CRC containing multiple abnormal stem-
lines (“DNA-multiploid tumors”) might have a more adverse
prognosis than those containing a single abnormal stemline (2,
3). In our own study, in fact, Cox proportional hazards analysis
of the patient subgroup with multiclonal tumors showed both a
higher risk of disease relapse and of death.
The prognostic value in CRC of SPF, despite the use of
different mathematical models, seems to be clearer. Literature
reports almost all agree that this biological variable is a major
determinant of biological aggressiveness and has a predictive
role in clinical outcome (5, 39). This is in accordance with our
results in which SPF was identified as independent prognostic
factor.
In conclusion, if our results on these biological indicators
(specific p53 mutations, DNA ploidy, and SPF) are confirmed
by large prospective studies, it will be possible to provide
additional and important useful information for prognosis and a
rational basis for the development of more specific clinical
treatments (more radical surgery, and/or adjuvant chemother-
apy or radiotherapy). In particular, efforts should therefore be
directed toward subsets of CRC patients with a high risk of
relapse or death, especially those with Dukes’ stages B (Astler-
Coller B2) and C. Furthermore, biomolecular variables of pre-
dictive relevance combined with pathological staging might be
considered as stratification factors in studies containing multi-
ple treatment approaches to identify biological indicators of
response to therapy.
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